secwatch.observer — SEC 8-K summary
======================================

Issuer:     CervoMed Inc. (CRVO)
CIK:        0001053691
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0001437749-25-008249
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

CervoMed reports Q4/FY2024 results; positive Phase 2b extension data for neflamapimod in DLB
--------------------------------------------------------------------------------

- Cash $38.9M at Dec 31, 2024 (up from $7.8M); funded into mid-2026.
- Net loss $16.3M for FY2024 vs $2.2M in 2023 (2023 included noncash gain).
- Positive 16-week extension results: improvement on CDR-SB (p<0.001 vs old capsules; p=0.003 vs placebo).
- Plan to initiate Phase 3 trial in mid-2026 after regulatory meetings.
- Added senior VPs Claudia Ordonez (Medical Science) and Mark De Rosch (Regulatory).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/0001437749-25-008249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053691/000143774925008249/crvo20250318_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-008249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer